The DOI matches its Crossref record; 181 of the 181 references it cites were found in a registry or an index.
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Abstract
During the past decades, better understanding of relapsing-remitting multiple sclerosis disease mechanisms have led to the development of several disease-modifying therapies, reducing relapse rates and severity, through immune system modulation or suppression. In contrast, current therapeutic options for progressive multiple sclerosis remain comparatively disappointing and challenging. One possible explanation is a lack of understanding of pathogenic mechanisms driving progressive multiple sclerosis. Furthermore, diagnosis is usually retrospective, based on history of gradual neurological worsening with or without occasional relapses, minor remissions or plateaus. In addition, imaging methods as well as biomarkers are not well established. Magnetic resonance imaging studies in progressive multiple sclerosis show decreased blood-brain barrier permeability, probably reflecting compartmentalization of inflammation behind a relatively intact blood-brain barrier. Interestingly, a spectrum of inflammatory cell types infiltrates the leptomeninges during subpial cortical demyelination. Indeed, recent magnetic resonance imaging studies show leptomeningeal contrast enhancement in subjects with progressive multiple sclerosis, possibly representing an in vivo marker of inflammation associated to subpial demyelination. Treatments for progressive disease depend on underlying mechanisms causing central nervous system damage. Immunity sheltered behind an intact blood-brain barrier, energy failure, and membrane channel dysfunction may be key processes in progressive disease. Interfering with these mechanisms may provide neuroprotection and prevent disability progression, while potentially restoring activity and conduction along damaged axons by repairing myelin. Although most previous clinical trials in progressive multiple sclerosis have yielded disappointing results, important lessons have been learnt, improving the design of novel ones. This review discusses mechanisms involved in progressive multiple sclerosis, correlations between histopathology and magnetic resonance imaging studies, along with possible new therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724 · cited 1×
“Based on autopsy studies, the general consensus now is that subpial lesions are abundant in progressive stages of multiple sclerosis (PPMS and SPMS) and rare in patients with acute or early stages of RRMS (Geurts and Barkhof, 2008; Trapp and Nave, 2008).”
BackgroundThe relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Magliozzi, R., Howell, O., Vora, A., Serafini, B., Nicholas, R., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,443
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403 · cited 2×
“Most phagocytic cells present ramified microglia morphology and appear in close apposition to neurites and neuronal cell bodies (Peterson et al., 2001).”
Background
Research works printed but not linked: 8
- Andersson, 1999, Multiple sclerosisthatis progressive from the time of onset: clinical characteristicsand progression of disability, Ann Neurol, 56, 1138
- 10.1136/jnnp.2010.205021 · doi:10.1136/jnnp.2010.205021
- Cadavid, 2015, BIIBo33, anti-LINGO treatment of relapsing-remitting Multiple Sclerosis: Basal data of the Phase 2 SYNERGY Trial, Neurology, 84 (14 Suppl), P7204, 10.1212/WNL.84.14_supplement.P7.204 · doi:10.1212/wnl.84.14_supplement.p7.204
- Cadavid, 2016, Evidence that the Anti-Lingo-1 monoclonal antibody BIIBo33protects against multifocal visual evoked potential amplitud loss in the fellow eye of subjects with unilateral acute optic neuritis, Neurology, 86 (16 Suppl), I10.009, 10.1212/WNL.86.16_supplement.I10.009 · doi:10.1212/wnl.86.16_supplement.i10.009
- 10.1007/s00415-011-6212-9 · DOI
- 10.1111/j.1755-5949.2008.00072.x · doi:10.1111/j.1755-5949.2008.00072.x
- 10.1191/1352458503ms970oa · doi:10.1191/1352458503ms970oa
- Tourbah A Lebrun-Frenay C Edan G Clanet M Papex C Vukusic S . 24-Month-treatment with-MD1003 (high doses of Biotin) in progressive multiple sclerosis: results of the MS-SPI trial extension phase. Neurology 2016; 86: Suppl S49.004 · doi:10.26226/morressier.59a3e8b7d462b8028d895787
Cited by
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Takata, F., Nakagawa, S., Matsumoto, J., & Dohgu, S. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661838 · Cited by 651
Epidemiology and treatment of multiple sclerosis in elderly populations
Vaughn, C. B., Jakimovski, D., Kavak, K. S., Ramanathan, M., Benedict, R. H. B., Zivadinov, R., & Weinstock-Guttman, B. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0183-3 · Cited by 306
Potential drug targets for multiple sclerosis identified through Mendelian randomization analysis
Lin, J., Zhou, J., & Xu, Y. (2023) · Brain · doi:10.1093/brain/awad070 · Cited by 271
“38 Considering the pathogenesis of PMS, which is characterized by chronic inflammation compartmentalized behind a closed blood–brain barrier, 3 we explored the causal proteins for MS not only in the plasma but also in the CSF and compared their effects thereafter.”
Secondary Progressive Multiple Sclerosis: New Insights
Cree, B. A. C., Arnold, D. L., Chataway, J., Chitnis, T., Fox, R. J., Pozo Ramajo, A., Murphy, N., & Lassmann, H. (2021) · Neurology · doi:10.1212/wnl.0000000000012323 · Cited by 260
Jamwal, S., Blackburn, J. K., & Elsworth, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107705 · Cited by 236
Elliott, C., Wolinsky, J. S., Hauser, S. L., Kappos, L., Barkhof, F., Bernasconi, C., Wei, W., Belachew, S., & Arnold, D. L. (2019) · Multiple Sclerosis Journal · doi:10.1177/1352458518814117 · Cited by 217
Multiple sclerosis and cognition: synaptic failure and network dysfunction
Di Filippo, M., Portaccio, E., Mancini, A., & Calabresi, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0053-9 · Cited by 205
Chronic inflammation in multiple sclerosis - seeing what was always there
Matthews, P. M. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0240-y · Cited by 128
Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets
Govindarajan, V., de Rivero Vaccari, J. P., & Keane, R. W. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01944-9 · Cited by 110
Premyelinating Oligodendrocytes: Mechanisms Underlying Cell Survival and Integration
Hughes, E. G., & Stockton, M. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.714169 · Cited by 98
The Notch pathway in CNS homeostasis and neurodegeneration
Ho, D. M., Artavanis‐Tsakonas, S., & Louvi, A. (2020) · WIREs Developmental Biology · doi:10.1002/wdev.358 · Cited by 90
An overall view of the most common experimental models for multiple sclerosis
Dedoni, S., Scherma, M., Camoglio, C., Siddi, C., Dazzi, L., Puliga, R., Frau, J., Cocco, E., & Fadda, P. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106230 · Cited by 79
Miedema, A., Gerrits, E., Brouwer, N., Jiang, Q., Kracht, L., Meijer, M., Nutma, E., Peferoen-Baert, R., Pijnacker, A. T. E., Wesseling, E. M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01306-3 · Cited by 65
Dietary Restriction and Neuroinflammation: A Potential Mechanistic Link
Bok, E., Jo, M., Lee, S., Lee, B.-R., Kim, J., & Kim, H.-J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030464 · Cited by 53
“Once the BBB construction is completed, the peripheral hematopoietic system does not further contribute to the microglia pool of the CNS under normal condition, meaning that the adult microglia population is maintained by self-renewal in the brain [56,57].”
BackgroundInfluentialmiR-124: A Promising Therapeutic Target for Central Nervous System Injuries and Diseases
Xu, J., Zheng, Y., Wang, L., Liu, Y., Wang, X., Li, Y., & Chi, G. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-021-01091-6 · Cited by 55
Jiang, J., Chu, C., Wu, C., Wang, C., Zhang, C., Li, T., Zhai, Q., Yu, L., Tian, F., & Chen, W. (2021) · Food & Function · doi:10.1039/d0fo03203d · Cited by 52
Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models
Zhan, J., Kipp, M., Han, W., & Kaddatz, H. (2021) · Immunology · doi:10.1111/imm.13395 · Cited by 49
Nylund, M., Sucksdorff, M., Matilainen, M., Polvinen, E., Tuisku, J., & Airas, L. (2022) · Brain Communications · doi:10.1093/braincomms/fcab301 · Cited by 48
TSPO-detectable chronic active lesions predict disease progression in multiple sclerosis
Polvinen, E., Matilainen, M., Nylund, M., Sucksdorff, M., & Airas, L. M. (2023) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000200133 · Cited by 36
“In most cases, multiple sclerosis (MS) begins as a relapsingremitting disease (RRMS), but many patients proceed to secondary progression characterized by gradual disability accumulation.(1) In secondary progressive MS (SPMS), trafficking of leukocytes from the periphery into the CNS and formation of focal inflammatory…”
BackgroundExosome-based drug delivery systems for enhanced neurological therapeutics
Vahab, S. A., V, V. K., & Kumar, V. S. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01710-x · Cited by 34
Qin, D., Wang, C., Li, D., & Guo, S. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105487 · Cited by 27
An Overview of Multiple Sclerosis In Vitro Models
Czpakowska, J., Kałuża, M., Szpakowski, P., & Głąbiński, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147759 · Cited by 7
Rayatpour, A., Foolad, F., & Javan, M. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03314-1 · Cited by 3
Metadata
- Authors
- Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-10-29
- Volume
- 140
- Issue
- 3
- Pages
- aww258
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2544079919
- Cited by
- 573
- References
- 181
- FWCI
- 23.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.